Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Myositis
What is your approach towards continuing cancer screening in a young adult with Tif-1+ dermatomyositis, and negative initial CT chest/abd/pelvis?
Related Questions
Do you screen for cardiac disease in patients with dermatomyositis in the absence of symptoms?
Is the efficacy and dose same for subcutaneous vs intravenous IVIGs being used for dermatomyositis?
How will you sequence therapies in dermatomyositis given the results of the ProDERM trial?
Is there a reason to repeat HMGCR antibody level for monitoring disease activity once documented positive in patients with IMNM?
How would you treat a patient with necrotizing myopathy with positive anti-HMHCoR Ab unresponsive to standard therapies?
Do you recommend discontinuing IVIG for a newly diagnosed HMGCR+ statin induced necrotizing myopathy who developed a recent brachial DVT?
How do you go about switching from one DMARD to another In patients with dermatomyositis that remains active?
What is your approach to elevated CK in patients without clinical or serologic evidence of immune mediated myopathy?
How would you approach a patient with elevated CPK in the 500-1000 range with no weakness on exam or myositis on MRI but with positive HMGCoA ab?
When do you consider the use of JAK inhibitors for cutaneous manifestations of myositis?
